


**IN THE CLAIMS**

1. (Original) A compound according to formula I



wherein R1 = -H, -CN, -COO<sup>+</sup>, -COS<sup>+</sup>, -COOH, -COSH, -COOR1.1, -COSR1.1, N-phthalimidyl,

wherein R1.1 = -H, C1-10 alkyl, C1-10 aralkyl or aryl,

wherein R2 = -H, C1-C4 alkyl, -OR1.1, -Hal (-F -Cl, -Br, -J), -NR2.1R2.2, -Am, -O-Am, -S-Am,

wherein R3 = -H, C1-C4 alkyl, -OR1.1, -Hal (-F -Cl, -Br, -J), -NR2.1R2.2, -Am, -O-Am, -S-Am,

wherein R2.1 = -H, C1-10 alkyl, C1-10 aralkyl or aryl,

wherein R2.2 = -H, C1-10 alkyl, C1-10 aralkyl or aryl,

wherein R2.1 and R2.2 may be identical or different,

wherein n and m may be identical or different and 0 to 10,

wherein o and p may be identical or different and 0 to 3,

wherein o > 0, if n and m = 0,

wherein R2 and R3 may be identical or different for Cn and/or Cm,

wherein R2 may be identical or different for every Cx = 1 ... n,

wherein R3 may be identical or different for every Cy = 1 ... m,

wherein -Am is an amino acid radical,

wherein q and r = 0 or 1 and identical or different,

wherein -Or- and/or -Oq- may also be replaced by -Sr- or -Sq-, resp.,

wherein -NR<sub>2.1</sub>R<sub>2.2</sub> may be replaced by a linear or branched -C<sub>1</sub>-C<sub>20</sub> alkyl, aralkyl or aryl,

wherein a group -CN, -(CO)-CN, -(CO)-O-R<sub>1</sub> or -(CO)-R<sub>1</sub> or -C-O-R<sub>1</sub> may be replaced by -SO<sub>2</sub>-NR<sub>2.1</sub>R<sub>2.2</sub>,

or a physiologically well tolerated salt of such a compound.

2. (Original) A compound according to claim 1, wherein R<sub>1</sub> = -CN.
3. (Currently Amended) A compound according to claim 1 or 2, wherein at least one of the R<sub>2</sub> exists at least singly as comprises -Am, wherein -Am preferably represents an amino acid radical of an essential amino acid, wherein in particular q = 0 and r = 1 or q = 1 and r = 0 or q = 1 and r = 1, m = 1, R<sub>3</sub> = -H, n = o = p = 0, R<sub>2.1</sub> = R<sub>2.2</sub> = -H.
4. (Currently Amended) A compound according to claim 1 or 2, wherein n = o = p = 0, wherein m = 0 to 4, wherein R<sub>2</sub> = R<sub>3</sub> = -H, or for at least one R<sub>2</sub>, R<sub>2</sub> = -AM<sub>m</sub>, wherein R<sub>2.1</sub> = R<sub>2.2</sub> = -H, wherein q = 0 and r = 1.
5. (Currently Amended) A compound according to claim 1 or 2, wherein m = p = 0, wherein o = 1, wherein n = 0 to 4, wherein R<sub>2</sub> = H, or for at least one R<sub>2</sub>, R<sub>2</sub> = -AM<sub>m</sub>, wherein R<sub>3</sub> = -H or -Hal in the case C<sub>x</sub> = 1, wherein R<sub>3</sub> = -H for all C<sub>x</sub> = n > 1, wherein R<sub>2.1</sub> = R<sub>2.2</sub> = -H, wherein q = 0 and r = 1.
6. (Currently Amended) A compound according to claim 1 or 2, wherein m = 1 to 4, wherein n = o = p = 0, wherein R<sub>2</sub> = H, or for at least one R<sub>2</sub>, R<sub>2</sub> = -AM<sub>m</sub>, wherein R<sub>3</sub> = -H or -Hal in the case C<sub>y</sub> = 1, wherein R<sub>3</sub> = -H for all C<sub>y</sub> = m > 1, wherein R<sub>2.1</sub> = R<sub>2.2</sub> = -H, wherein q = 0 and r = 1.

7. (Currently Amended) A compound according to claim 1 or 2, wherein  $o = p = 1$ , wherein  $m = 0$ , wherein  $n = 0$  to 4, wherein  $R_2 = R_3 = -H$ , or for at least one  $R_2$ ,  $R_2 = -AM_m$ , wherein  $R_{2.1} = R_{2.2} = -H$ , wherein  $q = 0$  and  $r = 1$ .
8. (Currently Amended) A compound according to claim 1 or 2, wherein  $n = p = 0$ , wherein  $o = 1$ , wherein  $m = 0$  to 4, wherein  $R_2 = R_3 = -H$ , or for at least one  $R_2$ ,  $R_2 = -AM_m$ , wherein  $R_{2.1} = R_{2.2} = -H$ , wherein  $q = 0$  and  $r = 1$ .
9. (Currently Amended) A compound according to claim 1 or 2, wherein  $m = p = 0$ , wherein  $o = 1$ , wherein  $n = 1$  to 4, wherein  $R_2 = R_3 = -H$ , or for at least one  $R_2$ ,  $R_2 = -AM_m$ , wherein  $R_{2.1} = R_{2.2} = -H$ , wherein  $q = 0$  and  $r = 1$ .
10. Cancelled
11. (Currently Amended) ~~The use of a compound according to Claim 1 for preparing a pharmaceutical composition~~ A method for treating one or several diseases of from the group comprising ["]cancer, chronic inflammations, asthma, arthritis, osteoarthritis, chronic polyarthritis, rheumatic arthritis, inflammatory bowl disease, degenerative joint diseases, rheumatic diseases with cartilage disorders, sepsis, autoimmune diseases, type I diabetes, Hashimoto thyroiditis, autoimmune thrombocytopenia, multiple sclerosis, myasthenia gravis, chronically inflammatory intestinal diseases, Crohn's disease, uveitis, psoriasis, collagenoses, Goodpasture syndrome, diseases with disturbed leukocyte adhesion, cachexia, diseases by increased TNF-alpha concentration, diabetes, adiposity, bacterial infections, ~~in particular with including those by antibiotic resistant bacteria (antibiotic)["]~~ comprising administering a pharmaceutical composition prepared comprising the compound according to Claim 1.
12. (Currently Amended) A pharmaceutical composition, wherein a compound according to Claim 1 is mixed with one or several physiologically well tolerated auxiliary substances and/or

carrier substances and galenically prepared for the local, ~~in particular~~ oral, or systemic, ~~in particular IV~~, administration comprising intravenous administration.

13. (Currently Amended) A method ~~The use of a compound according to Claim 1~~ for inhibiting in vivo the glycolysis and/or the glutaminolysis, ~~in particular~~ of pyruvate kinase, asparaginase, serine dehydratases, transaminases, glutamate oxalacetate transaminase, glutamate pyruvate transaminase, glutamate dehydrogenase, malate dehydrogenase, desaminases and/or glutaminases, ~~in particular~~ in prokaryotes and/or eukaryotes comprising administering a pharmaceutical composition comprising the compound according to Claim 1.